US 11,697,640 B2
Compounds for treating proliferative diseases
Bruce R. Zetter, Wayland, MA (US); and Lijun Sun, Harvard, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); and Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed by Children's Medical Center Corporation, Boston, MA (US); and Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed on May 4, 2021, as Appl. No. 17/307,922.
Application 17/307,922 is a division of application No. 15/779,685, granted, now 11,028,055, previously published as PCT/US2016/064256, filed on Nov. 30, 2016.
Claims priority of provisional application 62/261,240, filed on Nov. 30, 2015.
Prior Publication US 2022/0055993 A1, Feb. 24, 2022
Int. Cl. A61K 31/4184 (2006.01); A61K 31/4439 (2006.01); C07D 235/32 (2006.01); A61P 35/00 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 401/12 (2006.01)
CPC C07D 235/32 (2013.01) [A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61P 35/00 (2018.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01)] 20 Claims
 
1. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
R1 is substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl;
R2 is substituted or unsubstituted heteroaryl, —ORA, —N(RB)2,

OG Complex Work Unit Chemistry
RA is substituted or unsubstituted heterocyclyl;
RA2 is —N(RC)2, wherein each instance of RC is independently substituted or unsubstituted alkyl, or substituted or unsubstituted heterocyclyl;
RA3 is —N(RA4)2, wherein each instance of RA4 is independently substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; or two instances of RA4 are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;
each occurrence of RB is independently substituted or unsubstituted alkyl, substituted or unsubstituted carbocyclyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; or a nitrogen protecting group; or
two instances of RB are joined to form a substituted or unsubstituted, heterocyclic ring, or substituted or unsubstituted, heteroaryl ring;
R3 is hydrogen, substituted or unsubstituted C1-6 alkyl, or a nitrogen protecting group; and
R4 is hydrogen, substituted or unsubstituted C1-6 alkyl, or a nitrogen protecting group.